Dana-Farber-Cancer Institute Inc.

Novartis Ag

University of Michigan

Buhrlage, Sara

Griffin, James Douglas

Weisberg, Ellen

James Douglas Griffin

Paul William Manley

Stuart F Schlossman

Benedict R Lucchesi

Paul J Simpson

Robert F Todd, Iii

Sara Jean Buhrlage

Leigh Zawel

Scott A Armstrong

Ellen Weisberg

Martin Sattler

Anagha Deshpande

Doriano Fabbro

Stuart F Scholossman

The present invention is based, in part, on the identification of novel USP10 biomarkers and modulators, and methods of use thereof, for identifying, assessing, preventing, and treating AML.

Compositions and methods for identification, assessment, prevention, and treatment of AML using USP10 biomarkers and modulators

This present invention provides methods of treating of assessing/monitoring the responsiveness of a cancer cell to JAK inhibitor therapy.

Methods of predicting resistance to JAK inhibitor therapy

The present invention relates to a method of treating a warm-blooded animal, especially a human, having Mixed Lineage Leukemia (MLL rearranged ALL) comprising administering to said animal a therapeutically effective amount of a staurosporine derivative, especially PKC412 or a pharmaceutically acceptable salt thereof, alone or in combination with further therapeutic measures, for example, those defined herein; to the use of a staurosporine derivative for the preparation of a medicament for the treatment of MLL rearranged ALL; and to a commercial package comprising a staurosporine derivative together with instructions for its use in the treatment of MLL rearranged ALL.

Method of treating mixed lineage leukemia gene-rearranged acute lymphoblastic leukemias

The present invention relates to methods of treating hematological malignancies, including acute myeloid leukemia (AML), comprising the combination of a compound that inhibits the binding of the Smac protein to IAPs ('IAP inhibitor') and one or more pharmaceutically active agents; pharmaceutical compositions comprising said combination; and a commercial package comprising said combination. The present invention also relates to the use of IAP inhibitors in combination with one or more pharmaceutically active agents for the preparation of a medicament to treat hematological malignancies, including AML.

Combination of IAP inhibitors and FLT3 inhibitors

The present invention relates to the use of staurosporines derivatives for the preparation of a drug for the treatment of diseases involving deregulated FLT3 receptor tyrosine kinase activity, especially for the curative and/or prophylactic treatment of leukemias and myelodysplastic syndromes, and to a method of treating diseases involving deregulated FLT3 receptor tyrosine kinase activity.

Staurosporine derivatives as inhibitors of FLT3 receptor tyrosine kinase activity

A hybrid cell line is developed which produces a monoclonal antibody which binds to a unique antigenic site expressed on the surface of phagocytic cells. The monoclonal antibody binds to and activates a specific domain of the CD11b glycoprotein so as to inhibit adhesion dependent functions of the phagocytic cell, but it does not affect other phagocytic functions. This monoclonal antibody can be used as a reactant in an in vitro diagnostic immunoassay for detecting the unique antigenic site on the surface of normal human neutrophils.

Monoclonal antibody which inhibits the adhesion functions of the .beta.

Monoclonal antibody specific for the adhesion function domain of a

A method of reducing tissue injury in humans or other animal species using a monoclonal antibody to inhibit specific phagocyte functions. The monoclonal antibody is selected to bind to phagocytic leukocytes for the purpose of inhibiting migration to an inflammatory site in the body and to inhibit the adhesion and spreading of activated leukocytes reaching such an area and then, block release of toxic substances by these cells. The monoclonal antibody is administered in vivo prior or early in the course of an experience leading to an injurious inflammatory response such as can result from restoration of myocardial blood flow interrupted by an acute coronary thrombosis.

Method of reducing tissue damage at an inflammatory site using a

A hybrid cell line capable of producing monoclonal antibodies uniquely specific to human neutrophils. The monoclonal antibody has no reactivity with other human peripheral blood cells and virtually no reactivity with granulocyte precursors or other cells in bone marrow. Further, there is no reactivity with human acute leukemia cells. One of the partners in the hybridoma fusion of a mouse spleen cell developed from using highly purified human granulocytes as the immunization agent. The monoclonal antibody further is characterized by its capability of being used to enumerate and isolate neutrophils in normal peripheral blood and patients with acute leukemia.

Growing community of inventors

Brookline, MA, United States of America

James Douglas Griffin